Quantcast

Latest UCB Inc. Stories

2010-11-09 09:30:00

ATLANTA, Nov. 9, 2010 /PRNewswire/ -- Today, UCB, Inc. celebrates the academic success of the 2010 UCB Family Epilepsy Scholarship recipients. Over the past 6 years, UCB has awarded more than 200 scholarships, totaling over $1 million, to people whose lives have been directly affected by epilepsy, including those with epilepsy, their caregivers and family members. Epilepsy is a common neurological condition that can affect anyone at anytime. In the United States, 1 in 100 people are...

2010-11-02 09:30:00

ATLANTA, Nov. 2, 2010 /PRNewswire/ -- UCB, a global biopharmaceutical company long recognized for its commitment to the epilepsy community and patient-centered approach, will mark Epilepsy Awareness Month by rolling out new activities and resources at the national and local levels. These programs represent UCB's continued commitment to the epilepsy community and seek to empower patients and raise awareness about the condition. For photos, videos and background information go to:...

2010-10-14 09:00:00

ATLANTA, Oct. 14 /PRNewswire/ -- UCB, Inc., a global leader in the research and development of medications to treat immunology disorders, today announced the winners of its 2010 UCB Crohn's and Me Scholarship Program for outstanding individuals affected by this condition. UCB has selected 31 winners to receive a scholarship worth up to $10,000 to help them seek personal growth through higher education. The scholarship winners include Crohn's disease patients, as well as family members...

2010-09-30 11:00:00

BRUSSELS, Sept. 30 /PRNewswire/ -- People with Parkinson's disease who used once-daily Neupro® (rotigotine) in the RECOVER trial achieved improvements in quality of life, in addition to previously reported beneficial effects on motor and non-motor symptoms. Data presented this week at the 2nd World Parkinson Congress in Glasgow, UK, showed that Neupro® provided clinically relevant improvements in PDQ-8 score. This is a self-administered health-related...

2010-09-21 08:30:00

ATLANTA, Sept. 21 /PRNewswire/ -- UCB, Inc., a global biopharmaceutical leader in the research and development of medications to treat serious conditions including immunology disorders and central nervous system conditions, is proud to support people living beyond the boundaries of Crohn's disease, rheumatoid arthritis (RA) and epilepsy through three unique scholarship programs. In five years, UCB has awarded more than 400 scholarships--totaling more than $3 million--to individuals...

2010-07-28 07:00:00

BRUSSELS, July 28 /PRNewswire/ -- UCB today announced the results of a 6-month, randomized, double-blind, placebo-controlled clinical study, published in the journal Movement Disorders, showing that Neupro® (rotigotine transdermal system, 2 and 3 mg/24 hours) provided sustained, clinically relevant improvements in symptoms of Restless Legs Syndrome (RLS). The study also showed high rates of complete remission seen with rotigotine 2 mg or 3 mg/24 hours. "In this study...

2010-06-17 07:30:00

BRUSSELS, June 17 /PRNewswire-FirstCall/ -- New data presented this week at the 14th International Congress of Parkinson's Disease and Movement Disorders in Buenos Aires, Argentina (June 13-17, 2010) showed that Neupro® (rotigotine transdermal system) provided significantly greater improvement in early morning motor symptoms and sleep quality, compared with placebo, and as measured by the Unified Parkinson's Disease Rating Scale and the Parkinson's Disease Sleep Scale....

2010-06-14 10:30:00

ATLANTA, June 14 /PRNewswire/ -- Lt. Governor Casey Cagle today joined Georgia Bio, the Georgia Research Alliance, the Metro Atlanta Chamber and the Innovation Crescent business community in announcing the launch of the Georgia Bioscience Commercialization Center (GBCC), which will act as a start-up catalyst and resource center for bioscience entrepreneurs in Georgia. "The Georgia Bioscience Commercialization Center is a first of its kind initiative in Georgia, drawing on the expertise of...

2010-06-14 08:30:00

ATLANTA, June 14 /PRNewswire/ -- UCB today announced the availability of an oral solution formulation of Vimpat® (lacosamide) C-V, an antiepileptic drug (AED) for add-on treatment of partial-onset seizures in people with epilepsy age 17 years and older. Vimpat 10 mg/mL solution is now available in U.S. pharmacies. To view the multimedia assets associated with this release, please click: http://www.prnewswire.com/mnr/vimpat/34012/ Download a high resolution photograph...

2010-05-03 07:30:00

ATLANTA, May 3 /PRNewswire/ -- UCB and the Inflammatory Bowel Disease Working Group (IBDWG) today announced the five recipients of the 2010 Research Awards in Inflammatory Bowel Disease (IBD) for Gastroenterology (GI) Fellows, each of whom will receive a one-year $40,000 research grant for their original clinical or basic research. The recipients were selected by the IBDWG Steering Committee and the awards were funded by a grant from UCB, Inc. A reception honoring the recipients will be...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related